Diagnostic and molecular testing patterns in patients with newly diagnosed acute myeloid leukemia in the Connect ® MDS/AML Disease Registry
Year: 2020
Type: article
Study design: Observational Study
Abstract: Diagnostic and molecular genetic testing are key in advancing the treatment of acute myeloid leukemia (AML), yet little is known about testing patterns outside of clinical trials, especially in older patients. We analyzed diagnostic and molecular testing patterns over time in 565 patients aged ≥ 55 years with newly diagnosed AML enrolled in the Connect ® MDS/AML Disease Registry (NCT01688011) in the United States. Diagnostic data were recorded at enrolment and compared with published guidelines. The percentage of bone marrow blasts was reported for 82.1% of patients, and cellularity was the most commonly reported bone marrow morphological feature. Flow cytometry, karyotyping, molecular testing, and fluorescence in situ hybridization were performed in 98.8%, 95.4%, 75.9%, and 75.7% of patients, respectively. Molecular testing was done more frequently at academic than community/government sites (84.3% vs 70.2%; P < .001). Enrolment to the Registry after 2016 was significantly associated with molecular testing at academic sites (odds ratio [OR] 2.59; P = .023) and at community/government sites (OR 4.85; P < .001) in logistic regression analyses. Better understanding of practice patterns may identify unmet needs and inform institutional protocols regarding the diagnosis of patients with AML.
Source: eJHaem
DOI: 10.1002/jha2.16
Authors: Daniel A. Pollyea, Tracy I. George, Mehrdad Abedi, Rafael Bejar, Christopher R. Cogle, Kathryn Foucar, Guillermo Garcia‐Manero, David L. Grinblatt, Rami S. Komrokji, Jaroslaw P. Maciejewski, Dennis A. Revicki, Gail J. Roboz, Michael R. Savona, Bart L. Scott, Mikkael A. Sekeres, Michael A. Thompson, Sandra E. Kurtin, Chrystal U. Louis, Melissa Nifenecker, E. Dawn Flick, Arlene S. Swern, Pavel Kiselev, David P. Steensma, Harry P. Erba
Institutions: University of Colorado Anschutz, University of Utah, ARUP Laboratories (United States), University of California, Davis, University of California San Diego, Moores Cancer Center, University of Florida, University of New Mexico Health Sciences Center, The University of Texas MD Anderson Cancer Center, Endeavor Health, Moffitt Cancer Center, Cleveland Clinic, Weill Cornell Medicine, Vanderbilt University, Vanderbilt-Ingram Cancer Center, Fred Hutch Cancer Center, Aurora Health Care, University of Arizona Cancer Center, Bristol-Myers Squibb (United States), Dana-Farber Cancer Institute, Duke University
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,250
OpenAlex ID: W3038565975